Last 47 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
OptimizeRx Corporation's quarterly P/E stands at 11.8x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 24.56 | 11.79 | 128.13 | 41.87 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.13 | 1.84 | 3.74 | 2.20 | 1.82 | 0.69 | 1.66 | 2.43 | 2.80 | 2.23 | 1.98 | 4.39 | 4.81 |
| — | +166.1% | +125.3% | -9.4% | -34.9% | -68.9% | -16.2% | -44.8% | -41.7% | -41.8% | -55.1% | -50.5% | -60.8% | |
| P/B Ratio | 0.98 | 1.85 | 3.19 | 2.15 | 1.38 | 0.77 | 1.24 | 1.51 | 1.80 | 2.00 | 1.11 | 2.10 | 2.02 |
| — | +142.1% | +158.1% | +42.6% | -23.6% | -61.7% | +10.9% | -28.0% | -10.7% | -16.2% | -45.8% | -40.5% | -60.8% | |
| P/FCF | 6.62 | — | 30.54 | 14.10 | 10.42 | 286.90 | 20.81 | 65.49 | 28.09 | — | 28.11 | — | — |
| — | — | +46.7% | -78.5% | -62.9% | — | -25.9% | — | — | — | +44.5% | — | — | |
| EV / EBITDA | 6.55 | 5.67 | 33.35 | 15.78 | — | 5.78 | — | — | — | — | — | — | — |
| — | -1.9% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 8.97 | — | 45.28 | 20.29 | — | 7.25 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
OptimizeRx Corporation's operating margin was 26.6% in Q4 2025, up 18.7 pp QoQ and up 15.3 pp YoY. The trailing four-quarter average of 8.9% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 9.7% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.3% | 74.8% | 67.2% | 63.8% | 60.9% | 68.1% | 63.1% | 62.2% | 62.0% | 62.9% | 60.0% | 56.6% | 57.2% |
| — | +9.7% | +6.5% | +2.6% | -1.8% | +8.4% | +5.2% | +9.9% | +8.4% | -0.8% | -3.9% | -11.9% | -3.1% | |
| Operating Margin | 10.7% | 26.6% | 7.9% | 10.9% | -9.6% | 11.2% | -40.2% | -19.9% | -25.5% | -38.4% | -21.8% | -35.1% | -54.3% |
| — | +136.4% | +119.6% | +154.8% | +62.3% | +129.3% | -84.7% | +43.2% | +53.0% | -773.9% | +12.6% | -25.5% | -98.3% | |
| Net Margin | 4.7% | 15.6% | 3.0% | 5.2% | -10.0% | -0.2% | -42.8% | -21.3% | -35.0% | -14.6% | -17.5% | -30.1% | -49.2% |
| — | +6550.4% | +107.0% | +124.6% | +71.4% | +98.3% | -144.1% | +29.2% | +28.8% | -780.6% | +23.7% | -8.4% | -79.6% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | 4.0% | 0.6% | 1.3% | -1.9% | -0.1% | -7.7% | -3.3% | -5.5% | -3.4% | -2.5% | -3.5% | -5.1% |
| — | +6045.3% | +108.3% | +139.5% | +66.0% | +98.0% | -213.6% | +5.2% | -8.3% | -1239.1% | +3.7% | -21.4% | -78.5% | |
| ROA | 2.9% | 2.9% | 0.5% | 0.9% | -1.3% | -0.0% | -5.4% | -2.3% | -3.8% | -2.7% | -2.3% | -3.3% | -4.8% |
| — | +6331.5% | +108.5% | +139.6% | +66.2% | +98.3% | -131.0% | +30.2% | +20.2% | -1018.8% | +4.5% | -20.9% | -78.3% | |
| ROIC | 7.1% | 5.3% | 1.2% | 1.8% | -1.2% | 2.0% | -4.6% | -2.0% | -2.6% | -6.4% | -2.5% | -3.4% | -4.9% |
| — | +165.1% | +125.1% | +192.1% | +54.2% | +131.5% | -85.3% | +42.2% | +47.6% | -869.4% | +36.7% | +44.2% | +22.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
OptimizeRx Corporation's Debt/EBITDA ratio is 0.5x, down from 9.6x last quarter — comfortably within a safe range. The current ratio has improved 5.2% YoY to 3.04x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.23 | 0.24 | 0.28 | 0.28 | 0.31 | 0.30 | 0.30 | 0.29 | 0.00 | 0.00 | 0.00 |
| — | -87.1% | -25.0% | -18.5% | -5.2% | -2.5% | +24276.3% | +236560.3% | +17259.4% | +15552.3% | -34.8% | -93.6% | -25.3% | |
| Debt / EBITDA | 0.29 | 0.49 | 9.56 | 6.80 | — | 7.02 | — | — | — | — | — | — | — |
| — | -93.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.04 | 3.04 | 3.05 | 2.57 | 2.82 | 2.89 | 3.23 | 3.07 | 2.88 | 3.04 | 11.35 | 15.44 | 12.61 |
| — | +5.2% | -5.7% | -16.4% | -2.3% | -4.8% | -71.5% | -80.1% | -77.1% | -74.1% | -29.9% | -9.9% | -23.1% | |
| Quick Ratio | 3.04 | 3.04 | 3.05 | 2.57 | 2.82 | 2.89 | 3.23 | 3.07 | 2.88 | 3.04 | 11.35 | 15.44 | 12.61 |
| — | +5.2% | -5.7% | -16.4% | -2.3% | -4.8% | -71.5% | -80.1% | -77.1% | -74.1% | -29.9% | -9.9% | -23.1% | |
| Interest Coverage | — | — | 1.78 | 1.99 | -1.63 | 2.33 | -5.62 | -2.45 | -3.25 | -7.50 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying OPRX stock.
OptimizeRx Corporation's current P/E is 24.6x. The average P/E over the last 3 quarters is 60.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
OptimizeRx Corporation's current operating margin is 10.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking OptimizeRx Corporation's business trajectory between earnings reports.